Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

A/H Premium Weekly: BYD, Xinjiang Gold Wind, Ganfeng Lithium

A/H Premium Weekly: Arb Opportunities Last Week

A-H Premium Weekly: Shanghai Pharma, China Eastern Air, Huaneng Power, Shenzhen Hepalink

A/H Premium Weekly: Xinjiang Goldwind, Great Wall Motor, First Tractor

A/H Premium Weekly: Great Wall Motor, CCCC, Cansino, China Oilfield, Air China

A/H Premium Weekly: Utilities, Real Estate, Energy Lifted Premium

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

China Industrials / Quantitative Analysis

<ul>
<li>We analyse the changes of A/H premium on 136 stocks over the last week.</li>
<li>A/H premium increased by 5.7ppt WoW mainly driven by information technology and health care.</li>
<li>We highlight that 15 stocks reached their 52 week high of A/H premium last week.</li>
</ul>


We analyse the changes of A/H premium on 136 stocks over the last week.
A/H premium increased by 5.7ppt WoW mainly driven by information technology and health care.
We highlight that 15 stocks reached their 52 week high of A/H premium last week.


China Railway Signal & Communication (3969 HK)

Chongqing Iron & Steel Co Ltd H (1053 HK)

Zhengzhou Coal Mining Machinery Group Co (564 HK)

Beijing Chunlizhengda Medical Instruments (1858 HK)

Beijing Chunlizhengda Medical Instruments

Shandong Xinhua Pharmaceutical Company (719 HK)

Xinjiang Goldwind Science & Technology (2208 HK)

Shanghai Fudan Microelectronics H (1385 HK)

Shanghai Dazhong Public Utilities - H (1635 HK)

Asymchem Laboratories Tianjin (002821 CH)

Shenzhen HepaLink Pharmaceutical (H) (9989 HK)

A/H Premium Weekly: 15 Stocks at 52 Week High